Even a modest cohort size was sufficient to observe significantly reduced LMP1/LMP2A antigen‐specific CD8+ T cell immunity in newly diagnosed HLA‐A*02–versus HLA‐A*02+ EBV+cHL patients. This evidence concerns the gene PDLIM7 and classic Hodgkin lymphoma.